KRW 1446.0
(-0.69%)
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2023 | 422.03 Million KRW | -55.36% |
2022 | 945.41 Million KRW | 128.88% |
2021 | -3.27 Billion KRW | -141.36% |
2020 | -1.35 Billion KRW | -57.48% |
2019 | -861.18 Million KRW | -114.35% |
2018 | -401.76 Million KRW | 23.23% |
2017 | -523.35 Million KRW | 13.93% |
2016 | -608.05 Million KRW | -98.73% |
2015 | -305.96 Million KRW | 0.0% |
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2024 Q1 | 282.69 Million KRW | 822.06% |
2024 Q2 | 53.85 Million KRW | 11.67% |
2023 Q1 | 2.29 Million KRW | -99.14% |
2023 Q3 | 408.88 Million KRW | 717.66% |
2023 Q4 | -39.15 Million KRW | -109.58% |
2023 Q2 | 50 Million KRW | 2081.37% |
2023 FY | 422.03 Million KRW | -55.36% |
2022 Q2 | 173.49 Million KRW | -12.82% |
2022 FY | 945.41 Million KRW | 128.88% |
2022 Q4 | 265.57 Million KRW | 306.4% |
2022 Q3 | 65.34 Million KRW | -62.33% |
2022 Q1 | 199 Million KRW | 106.97% |
2021 FY | -3.27 Billion KRW | -141.36% |
2021 Q2 | -718.55 Million KRW | -538.31% |
2021 Q3 | 135.45 Million KRW | 118.85% |
2021 Q4 | -2.85 Billion KRW | -2207.05% |
2021 Q1 | 163.93 Million KRW | 108.93% |
2020 Q1 | 171.28 Million KRW | 328.71% |
2020 FY | -1.35 Billion KRW | -57.48% |
2020 Q4 | -1.83 Billion KRW | -1432.78% |
2020 Q3 | 137.76 Million KRW | -50.24% |
2020 Q2 | 276.85 Million KRW | 61.63% |
2019 FY | -861.18 Million KRW | -114.35% |
2019 Q4 | -74.89 Million KRW | -201.64% |
2019 Q3 | 73.68 Million KRW | 0.0% |
2018 FY | -401.76 Million KRW | 23.23% |
2017 FY | -523.35 Million KRW | 13.93% |
2016 FY | -608.05 Million KRW | -98.73% |
2015 FY | -305.96 Million KRW | 0.0% |
Name | Gross Profit | Gross Profit Difference |
---|---|---|
Osang Healthcare Co.,Ltd | 219.75 Billion KRW | 99.808% |
InBody Co.,Ltd | 128.11 Billion KRW | 99.671% |
Curexo Inc. | 17.95 Billion KRW | 97.65% |
Seegene, Inc. | 180.07 Billion KRW | 99.766% |
i-SENS, Inc. | 101.04 Billion KRW | 99.582% |
Ray Co., Ltd. | 65.08 Billion KRW | 99.352% |
Sugentech Inc. | -5.88 Billion KRW | 107.176% |
L&C Bio Co., Ltd | 32.52 Billion KRW | 98.703% |